会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 52. 发明申请
    • TEMPORALLY CONTROLLED DRUG DELIVERY SYSTEMS
    • 临时控制的药物输送系统
    • WO1995028144A1
    • 1995-10-26
    • PCT/IB1995000223
    • 1995-04-03
    • CIBA-GEIGY AGGIANNOS, Steven, AndrewMINH DINH, StevenBERNER, Bret
    • CIBA-GEIGY AG
    • A61K09/00
    • A61K9/7084A61K9/0002
    • A delivery mechanism and device for the passive periodic release of a drug or an active ingredient which avoids the need for external power sources and/or electronic controllers. By taking advantage of oscillating chemical systems, one can change the pH of a solution, a drug, enhancer or solubilizer resulting in oscillating the ability of an active ingredient to be delivered transdermally. The pH of a solution can be oscillated over a range of pH values from 2 to 10 by the reduction and oxidation (redox) reactions of salts, such as permanganates, iodates, sulfates, chlorates, or bromates. Upon activation, the delivery system conditions begin to oscillate and with it, the delivery of the active agent oscillates.
    • 用于药物或活性成分的被动定期释放的递送机制和装置,其避免需要外部电源和/或电子控制器。 通过利用振荡化学系统,可以改变溶液,药物,增强剂或增溶剂的pH,导致活性成分经皮递送的能力的振荡。 通过盐,如高锰酸盐,碘酸盐,硫酸盐,氯酸盐或溴酸盐的还原和氧化(氧化还原)反应,溶液的pH可以在2至10的pH范围内振荡。 在激活时,递送系统条件开始振荡并且随之而起,活性剂的递送振荡。
    • 58. 发明申请
    • N,N'-BIS(2-HYDROXYBENZYL)ETHYLENEDIAMINE-N,N'-DIACETIC ACID DERIVATIVES AS CHELATING AGENTS
    • N,N'-BIS(2-羟基苄基)乙烯二胺-N,N'-二酸衍生物作为螯合剂
    • WO1995016663A1
    • 1995-06-22
    • PCT/IB1994000388
    • 1994-12-05
    • CIBA-GEIGY AGGASPARINI, FabrizioLEUTERT, ThomasFARLEY, David, L.
    • CIBA-GEIGY AG
    • C07C229/16
    • C07D295/185C07C229/16C07C235/06C07D317/40
    • [N,N'-bis(2-hydroxybenzyl)ethylenediamine N,N'-diacetic acid] derivatives of formula (I) in which R represents -(CO)-R1, -O-(CO)-R2, -O-(CO)-O-R3 or (a) wherein R1 is -NR4R5 or (III); whereby R4 and R5 are independent of each other C1-C3 alkyl or C3-C7 cycloalkyl or form together the group -(CH2)n-, n is an integer from 3 to 6; R2 is C1-C6 alkyl, unsubstituted phenyl or phenyl substituted by one to four substituents selected from the group consisting of halogen and hydroxy; R3 is C1-C6 alkyl or C3-C7 cycloalkyl; R4 is C1-C3 alkyl; and salts thereof form chelate-type metal complexes with trivalent metal ions, especially iron (III), and can be used, for example, for the treatment of pathological conditions in warm-blooded animals that are associated with an excess of trivalent metal ions in the body.
    • 式(I)的[N,N'-双(2-羟基苄基)乙二胺N,N'-二乙酸]衍生物,其中R表示 - (CO)-R1,-O-(CO)-R2,-O- (CO)-O-R3或(a)其中R1是-NR4R5或(III); 其中R 4和R 5彼此独立地为C 1 -C 3烷基或C 3 -C 7环烷基或一起形成 - (CH 2)n - ,n为3至6的整数; R2是C1-C6烷基,未取代的苯基或被一至四个选自卤素和羟基的取代基取代的苯基; R3是C1-C6烷基或C3-C7环烷基; R4是C1-C3烷基; 其盐与三价金属离子特别是铁(III)形成螯合型金属络合物,并且可用于例如治疗与过量三价金属离子相关的温血动物的病理状况 身体。
    • 59. 发明申请
    • C5a RECEPTOR ANTAGONISTS HAVING SUBSTANTIALLY NO AGONIST ACTIVITY
    • C5a受体拮抗剂具有主要的无激素活性
    • WO1995016033A1
    • 1995-06-15
    • PCT/IB1994000359
    • 1994-11-16
    • CIBA-GEIGY AGVAN OOSTRUM, JanBOYAR, William, C.GALAKATOS, Nicholas, G.PEPPARD, Jane, V.
    • CIBA-GEIGY AG
    • C12N15/12
    • C07K14/472A61K38/00C07K16/18C07K2319/00
    • Disclosed are polypeptide analogues of human C5a which are C5a receptor antagonists that exhibit substantially no analphylatoxin or agonist activity, and derivatives of the analogues, and dimeric forms of the analogues or derivatives. DNA molecules encoding the polypeptides and methods of making the analogues are also provided. Pharmaceutical formulations containing a C5a analogue are used therapeutically in the treatment of C5a-mediated diseases and inflammatory conditions in mammals, and prophylactically to prevent or reduce inflammation caused by an event which causes inflammation or aggravates an existing inflammatory condition, respectively. Further disclosed are antibodies specific to the C5a analogues, derivatives thereof, and dimers of the analogues and derivatives which exhibit substantially no cross-reactivity with human C5a. The antibodies are used to detect or quantify circulating C5a analogue or derivative, as well as to modify, e.g., neutralize, the activity of the C5a receptor antagonist in vivo.
    • 公开了人C5a的多肽类似物,其是显示基本上没有分泌毒素或激动剂活性的C5a受体拮抗剂,以及类似物的衍生物和类似物或衍生物的二聚体形式。 还提供了编码多肽的DNA分子和制备类似物的方法。 含有C5a类似物的药物制剂治疗性地用于治疗哺乳动物中C5a介导的疾病和炎性病症,并预防性地预防或减少由引起炎症或加剧现有炎性病症的事件引起的炎症。 进一步公开的是对C5a类似物,其衍生物和类似物和衍生物的二聚体特异的抗体,其表现出与人C5a基本上没有交叉反应性。 所述抗体用于检测或定量循环C5a类似物或衍生物,以及修饰,例如中和体内C5a受体拮抗剂的活性。
    • 60. 发明申请
    • NOVEL SUBSTITUED THIOSEMICARBAZONETHIONES
    • 新的替代硫代磷酸盐
    • WO1995014686A1
    • 1995-06-01
    • PCT/EP1994003778
    • 1994-11-15
    • CIBA-GEIGY AGMISSBACH, Martin
    • CIBA-GEIGY AG
    • C07D279/06
    • C07D279/06
    • The present invention relates to novel substituted thiosemicarbazonethiones containing 6-ring members of formula (I) wherein R1 is lower alkyl, lower alk-2-en-1-yl, lower alk-2-yn-1-yl, or aryl-lower alkyl, R2 is hydrogen, lower alkyl, lower alk-2-en-1-yl, lower alk-2-yn-1-yl, aryl, aryl-lower alkyl, unsaturated or saturated heterocyclyl-lower alkyl, lower alkoxycarbonyl-lower alkyl or a group -C(=O)-R3 or -C(=S)-R3, wherein R3 is lower alkyl, aryl, aryl-lower alkyl, aryl-lower alkenyl, heteroaryl (hetaryl), aryloxy, aryl-lower alkoxy or lower alk-2-en-1-yloxy, and the salts thereof, to a process for the preparation of said compounds, to pharmaceutical compositions containing them, and to the use thereof as medicaments.
    • 本发明涉及含有式(I)的6-环成员的新型取代的缩氨基硫脲,其中R1是低级烷基,低级烯-2-烯-1-基,低级烯-2-炔-1-基或芳基低级 烷基,R 2是氢,低级烷基,低级烯-2-烯-1-基,低级烷-2-炔-1-基,芳基,芳基 - 低级烷基,不饱和或饱和的杂环基 - 低级烷基,低级烷氧基羰基 - 低级 烷基或基团-C(= O)-R 3或-C(= S)-R 3,其中R 3是低级烷基,芳基,芳基 - 低级烷基,芳基 - 低级烯基,杂芳基(杂芳基),芳氧基, 烷氧基或低级烯-2-烯-1-基氧基及其盐与制备所述化合物的方法,含有它们的药物组合物及其作为药物的用途。